Home LiteratureArticle Details
PMID: 20484397 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Susceptibility pathways in Fanconi's anemia and breast cancer.

The New England journal of medicine ·Vol. 362 ·No. 20 ·2010-05-20 ·Pages 1909-19

D'Andrea AD

Abstract

暂无摘要

MeSH Terms
Breast Neoplasms/genetics DNA Methylation DNA Repair/physiology Epigenesis, Genetic Fanconi Anemia/diagnosis,genetics,therapy Fanconi Anemia Complementation Group Proteins/genetics,metabolism,physiology Female Genes, BRCA2 Genetic Predisposition to Disease Germ-Line Mutation Humans Metabolic Networks and Pathways Mutation Ovarian Neoplasms/genetics
Chemicals
Fanconi Anemia Complementation Group Proteins
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
D'Andrea Alan D
Department of Radiation Oncology, Dana-Farber Cancer Institute, Children's Hospital, and Harvard Medical School, Boston, MA 02115, USA. [email protected]
References (117)
117 references, click to expand
  1. The Fanconi anemia/BRCA pathway: a coordinator of cross-link repair.
    Exp Cell Res. 2006 Aug 15;312(14):2647-53 PMID: 16859679
  2. Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways.
    Hum Mol Genet. 2004 Jun 15;13(12):1241-8 PMID: 15115758
  3. Positional cloning of a novel Fanconi anemia gene, FANCD2.
    Mol Cell. 2001 Feb;7(2):241-8 PMID: 11239453
  4. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors.
    Mol Cancer. 2009 Apr 16;8:24 PMID: 19371427
  5. The two faces of BRCA2, a FANCtastic discovery.
    Mol Cell. 2002 Jul;10(1):2-4 PMID: 12150898
  6. Deubiquitination of FANCD2 is required for DNA crosslink repair.
    Mol Cell. 2007 Dec 14;28(5):798-809 PMID: 18082605
  7. How the fanconi anemia pathway guards the genome.
    Annu Rev Genet. 2009;43:223-49 PMID: 19686080
  8. Fanconi anemia diagnosis and the diepoxybutane (DEB) test.
    Exp Hematol. 1993 Jun;21(6):731-3 PMID: 8500573
  9. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival.
    Oncogene. 2004 Jan 29;23(4):1000-4 PMID: 14647419
  10. The Fanconi anaemia/BRCA pathway.
    Nat Rev Cancer. 2003 Jan;3(1):23-34 PMID: 12509764
  11. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M.
    Nat Genet. 2005 Sep;37(9):958-63 PMID: 16116422
  12. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair.
    Science. 2009 Dec 18;326(5960):1698-701 PMID: 19965384
  13. The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients.
    Cancer Cell. 2002 Mar;1(2):129-32 PMID: 12086871
  14. Fanconi anemia gene mutations in young-onset pancreatic cancer.
    Cancer Res. 2003 May 15;63(10):2585-8 PMID: 12750283
  15. Identification of the Fanconi anemia complementation group I gene, FANCI.
    Cell Oncol. 2007;29(3):211-8 PMID: 17452773
  16. Recruitment of fanconi anemia and breast cancer proteins to DNA damage sites is differentially governed by replication.
    Mol Cell. 2009 Sep 11;35(5):716-23 PMID: 19748364
  17. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.
    Nat Genet. 2007 Feb;39(2):159-61 PMID: 17200672
  18. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
    Lancet. 1994 Mar 19;343(8899):692-5 PMID: 7907678
  19. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells.
    Nature. 2009 Jul 2;460(7251):53-9 PMID: 19483674
  20. Fanconi anemia.
    Semin Hematol. 2006 Jul;43(3):147-56 PMID: 16822457
  21. The Fanconi anemia signalosome anchor.
    Mol Cell. 2007 Feb 23;25(4):487-90 PMID: 17317622
  22. Meta-analysis of BRCA1 and BRCA2 penetrance.
    J Clin Oncol. 2007 Apr 10;25(11):1329-33 PMID: 17416853
  23. Interaction of FANCD2 and NBS1 in the DNA damage response.
    Nat Cell Biol. 2002 Dec;4(12):913-20 PMID: 12447395
  24. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene.
    Science. 2009 Apr 10;324(5924):217 PMID: 19264984
  25. Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype.
    Dev Cell. 2009 Feb;16(2):314-20 PMID: 19217432
  26. Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia.
    Cell Oncol. 2008;30(4):299-306 PMID: 18607065
  27. Cell cycle-dependent chromatin loading of the Fanconi anemia core complex by FANCM/FAAP24.
    Blood. 2008 May 15;111(10):5215-22 PMID: 18174376
  28. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
    Nat Med. 2003 May;9(5):568-74 PMID: 12692539
  29. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway.
    Mol Cancer Ther. 2006 Apr;5(4):952-61 PMID: 16648566
  30. A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway.
    Mol Cell. 2007 Dec 14;28(5):786-97 PMID: 18082604
  31. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer.
    Gastroenterology. 2009 Sep;137(3):1183-6 PMID: 19635604
  32. BLM and the FANC proteins collaborate in a common pathway in response to stalled replication forks.
    EMBO J. 2004 Aug 4;23(15):3154-63 PMID: 15257300
  33. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.
    Mol Cell. 2001 Feb;7(2):249-62 PMID: 11239454
  34. FANCM and FAAP24 function in ATR-mediated checkpoint signaling independently of the Fanconi anemia core complex.
    Mol Cell. 2008 Nov 7;32(3):313-24 PMID: 18995830
  35. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
    J Mol Med (Berl). 2007 May;85(5):497-509 PMID: 17221219
  36. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
    Cancer Res. 2006 Aug 15;66(16):8109-15 PMID: 16912188
  37. FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3.
    Oncogene. 2008 Jun 12;27(26):3641-52 PMID: 18212739
  38. Cancer in Fanconi anemia.
    Blood. 2003 Mar 1;101(5):2072 PMID: 12584146
  39. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
    Nature. 2005 Apr 14;434(7035):917-21 PMID: 15829967
  40. Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers.
    Breast Cancer Res Treat. 2008 Sep;111(1):113-20 PMID: 17932744
  41. The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations.
    Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2357-62 PMID: 14983014
  42. Familial pancreatic cancer: from genes to improved patient care.
    Expert Rev Gastroenterol Hepatol. 2007 Oct;1(1):81-8 PMID: 19072437
  43. FANCM connects the genome instability disorders Bloom's Syndrome and Fanconi Anemia.
    Mol Cell. 2009 Dec 25;36(6):943-53 PMID: 20064461
  44. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ.
    Cancer Cell. 2005 Sep;8(3):255-65 PMID: 16153896
  45. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
    N Engl J Med. 2009 Jul 9;361(2):123-34 PMID: 19553641
  46. Functional defects in the fanconi anemia pathway in pancreatic cancer cells.
    Am J Pathol. 2004 Aug;165(2):651-7 PMID: 15277238
  47. Case records of the Massachusetts General Hospital. Case 13-2006. A 50-year-old man with a painful bone mass and lesions in the liver.
    N Engl J Med. 2006 Apr 27;354(17):1828-37 PMID: 16641400
  48. Tempol protects against oxidative damage and delays epithelial tumor onset in Fanconi anemia mice.
    Cancer Res. 2008 Mar 1;68(5):1601-8 PMID: 18316625
  49. BRCA-FA pathway as a target for anti-tumor drugs.
    Anticancer Agents Med Chem. 2008 May;8(4):426-30 PMID: 18473727
  50. Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot.
    Cancer Biol Ther. 2004 Jun;3(6):534-7 PMID: 15107617
  51. CpG island methylation of DNA damage response genes in advanced ovarian cancer.
    Cancer Res. 2005 Oct 1;65(19):8961-7 PMID: 16204069
  52. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins.
    Nat Rev Genet. 2007 Oct;8(10):735-48 PMID: 17768402
  53. Subtyping analysis of Fanconi anemia by immunoblotting and retroviral gene transfer.
    Mol Med. 1998 Jul;4(7):468-79 PMID: 9713825
  54. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin.
    Mol Cancer. 2004 Dec 01;3:33 PMID: 15574200
  55. A novel cell-free screen identifies a potent inhibitor of the Fanconi anemia pathway.
    Int J Cancer. 2009 Feb 15;124(4):783-92 PMID: 19048618
  56. Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer.
    Cancer Res. 2007 Oct 1;67(19):9591-6 PMID: 17909071
  57. Hypomutability in Fanconi anemia cells is associated with increased deletion frequency at the HPRT locus.
    Proc Natl Acad Sci U S A. 1990 Nov;87(21):8383-7 PMID: 2236046
  58. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
    Nature. 2005 Apr 14;434(7035):913-7 PMID: 15829966
  59. Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for fanconi anemia pathway function and BRCA2 interaction.
    Cancer Res. 2009 Nov 15;69(22):8775-83 PMID: 19861535
  60. Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia.
    Blood. 2004 Apr 15;103(8):3226-9 PMID: 15070707
  61. FANCI is a second monoubiquitinated member of the Fanconi anemia pathway.
    Nat Struct Mol Biol. 2007 Jun;14(6):564-7 PMID: 17460694
  62. A novel ubiquitin ligase is deficient in Fanconi anemia.
    Nat Genet. 2003 Oct;35(2):165-70 PMID: 12973351
  63. PALB2 is an integral component of the BRCA complex required for homologous recombination repair.
    Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7155-60 PMID: 19369211
  64. FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway.
    Nat Struct Mol Biol. 2008 Nov;15(11):1138-46 PMID: 18931676
  65. ATR couples FANCD2 monoubiquitination to the DNA-damage response.
    Genes Dev. 2004 Aug 15;18(16):1958-63 PMID: 15314022
  66. Preimplantation diagnosis for Fanconi anemia combined with HLA matching.
    JAMA. 2001 Jun 27;285(24):3130-3 PMID: 11427142
  67. The Fanconi family adds a fraternal twin.
    Dev Cell. 2007 May;12(5):661-2 PMID: 17488615
  68. PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
    Curr Biol. 2009 Mar 24;19(6):524-9 PMID: 19268590
  69. DNA repair pathways as targets for cancer therapy.
    Nat Rev Cancer. 2008 Mar;8(3):193-204 PMID: 18256616
  70. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer.
    Nat Genet. 2007 Feb;39(2):162-4 PMID: 17200671
  71. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.
    Nat Genet. 2005 Sep;37(9):931-3 PMID: 16116424
  72. The FANC pathway and BLM collaborate during mitosis to prevent micro-nucleation and chromosome abnormalities.
    Nat Cell Biol. 2009 Jun;11(6):761-8 PMID: 19465921
  73. A 20-year perspective on the International Fanconi Anemia Registry (IFAR).
    Blood. 2003 Feb 15;101(4):1249-56 PMID: 12393516
  74. The Fanconi anemia core complex is required for efficient point mutagenesis and Rev1 foci assembly.
    DNA Repair (Amst). 2008 Jun 1;7(6):902-11 PMID: 18448394
  75. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway.
    Mol Cell. 2005 Feb 4;17(3):331-9 PMID: 15694335
  76. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia.
    J Natl Cancer Inst. 2003 Oct 15;95(20):1548-51 PMID: 14559878
  77. Subtyping of Fanconi anemia patients: implications for clinical management.
    Blood. 2003 Nov 1;102(9):3459 PMID: 14568911
  78. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells.
    Mol Cell. 1998 Sep;2(3):317-28 PMID: 9774970
  79. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.
    Cancer Res. 2004 May 1;64(9):2994-7 PMID: 15126331
  80. Regulation of monoubiquitinated PCNA by DUB autocleavage.
    Nat Cell Biol. 2006 Apr;8(4):339-47 PMID: 16531995
  81. The emerging landscape of breast cancer susceptibility.
    Nat Genet. 2008 Jan;40(1):17-22 PMID: 18163131
  82. A novel diagnostic screen for defects in the Fanconi anemia pathway.
    Blood. 2002 Dec 15;100(13):4649-54 PMID: 12393398
  83. Gene therapy in the treatment of Fanconi anemia, a progressive bone marrow failure syndrome.
    Curr Opin Mol Ther. 2005 Oct;7(5):461-6 PMID: 16248281
  84. Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells.
    Br J Haematol. 2000 Dec;111(4):1057-64 PMID: 11167740
  85. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
    Hum Mol Genet. 2003 Oct 1;12(19):2503-10 PMID: 12915460
  86. Tracing the network connecting BRCA and Fanconi anaemia proteins.
    Nat Rev Cancer. 2004 Apr;4(4):266-76 PMID: 15057286
  87. BRCA2 germline mutations in familial pancreatic carcinoma.
    J Natl Cancer Inst. 2003 Feb 5;95(3):214-21 PMID: 12569143
  88. Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia.
    Br J Haematol. 2003 Nov;123(3):469-71 PMID: 14617007
  89. Resistance to therapy caused by intragenic deletion in BRCA2.
    Nature. 2008 Feb 28;451(7182):1111-5 PMID: 18264088
  90. Inherited susceptibility to common cancers.
    N Engl J Med. 2008 Nov 13;359(20):2143-53 PMID: 19005198
  91. Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM.
    Mol Cell. 2007 Feb 9;25(3):331-43 PMID: 17289582
  92. Structural basis for recruitment of BRCA2 by PALB2.
    EMBO Rep. 2009 Sep;10(9):990-6 PMID: 19609323
  93. Diagnosis of fanconi anemia by diepoxybutane analysis.
    Curr Protoc Hum Genet. 2003 Jul;Chapter 8:Unit 8.7 PMID: 18428345
  94. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.
    Science. 2002 Sep 13;297(5588):1837-48 PMID: 12228710
  95. Involvement of Brca2 in DNA repair.
    Mol Cell. 1998 Feb;1(3):347-57 PMID: 9660919
  96. Biallelic inactivation of BRCA2 in Fanconi anemia.
    Science. 2002 Jul 26;297(5581):606-9 PMID: 12065746
  97. Hallmarks of 'BRCAness' in sporadic cancers.
    Nat Rev Cancer. 2004 Oct;4(10):814-9 PMID: 15510162
  98. Direct DNA binding activity of the Fanconi anemia D2 protein.
    J Biol Chem. 2005 Jun 24;280(25):23593-8 PMID: 15849361
  99. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer.
    Cancer Res. 2005 Jan 15;65(2):383-6 PMID: 15695377
  100. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Eur J Cancer. 2002 Nov;38 Suppl 6:S15-7 PMID: 12409058
  101. Fanconi anemia and its diagnosis.
    Mutat Res. 2009 Jul 31;668(1-2):4-10 PMID: 19622403
  102. No evidence for FANCF gene silencing in head-and-neck squamous cell carcinomas.
    Cell Oncol. 2009;31(1):53-6 PMID: 19096150
  103. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
    Nature. 2008 Feb 28;451(7182):1116-20 PMID: 18264087
  104. Diagnosis, genetics, and management of inherited bone marrow failure syndromes.
    Hematology Am Soc Hematol Educ Program. 2007;:29-39 PMID: 18024606
  105. The Walker B motif in avian FANCM is required to limit sister chromatid exchanges but is dispensable for DNA crosslink repair.
    Nucleic Acids Res. 2009 Jul;37(13):4360-70 PMID: 19465393
  106. Targeted therapy for cancer using PARP inhibitors.
    Curr Opin Pharmacol. 2008 Aug;8(4):363-9 PMID: 18644251
  107. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents.
    Biochem Soc Trans. 2004 Dec;32(Pt 6):959-61 PMID: 15506935
  108. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
    Science. 2003 Oct 24;302(5645):643-6 PMID: 14576434
  109. A growing network of cancer-susceptibility genes.
    N Engl J Med. 2003 May 8;348(19):1917-9 PMID: 12736286
  110. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways.
    Cell. 2002 May 17;109(4):459-72 PMID: 12086603
  111. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J.
    Nat Genet. 2005 Sep;37(9):934-5 PMID: 16116423
  112. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
    Mol Cancer. 2009 Jul 14;8:48 PMID: 19602291
  113. BRCA2 mutations in primary breast and ovarian cancers.
    Nat Genet. 1996 Jun;13(2):238-40 PMID: 8640235
  114. Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia.
    Leukemia. 2004 Mar;18(3):420-5 PMID: 14749703
  115. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
    Nucleic Acids Res. 2006 Mar 23;34(6):1685-91 PMID: 16556909
  116. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair.
    Cell. 2007 Apr 20;129(2):289-301 PMID: 17412408
  117. High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells.
    Cancer Res. 2007 Mar 1;67(5):2169-77 PMID: 17332347
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
1533-4406
DOI
10.1056/NEJMra0809889
Email
[email protected]
Published
2010-05-20
Pages
1909-19
Language
English
Region
United States
NLM ID
0255562
PMCID
PMC3069698
Subset
IM
Grants
NCI NIH HHS · P01 CA092584-09 · United States
NHLBI NIH HHS · R37 HL052725 · United States
NHLBI NIH HHS · R01 HL052725 · United States
PHS HHS · U19A1067751 · United States
NIAID NIH HHS · U19 AI067751 · United States
NCI NIH HHS · P01 CA092584 · United States
NHLBI NIH HHS · R01HL52725 · United States
NCI NIH HHS · P01CA092584 · United States
NIDDK NIH HHS · R01DK43889 · United States
NIDDK NIH HHS · R01 DK043889-18 · United States
NIAID NIH HHS · U19 AI067751-05 · United States
NIDDK NIH HHS · R01 DK043889 · United States
NHLBI NIH HHS · R37 HL052725-17 · United States
External Links
PubMed source DOI: 10.1056/NEJMra0809889 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2